Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A) . Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) [1][2].
Product Specifications
CAS Number
1228763-95-8
Product Name Alternative
IPH2201
UNSPSC
12352203
Target
Checkpoint Kinase (Chk) ; IFNAR
Type
Inhibitory Antibodies
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/monalizumab.html
Purity
99.93
Solubility
H2O
Smiles
[Monalizumab]
Molecular Weight
(146.3 kDa)
References & Citations
[1]Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7 (1) :263.|[2]Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel) . 2020 Sep 21;12 (9) :2691.|[3]McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5 (10) :e1226720.|[4]Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15 (11) :e17804.|[5]Maximilian Pinho-Schwermann, et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade.doi https://doi.org/10.1101/2023.11.15.567201
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
256202 Pack of 10 Tag(s)
TAG-F NE PAS METTRE EN M.-75X160MM AC Signs
Sign In for Pricing
View Details